Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Overview of attention for article published in Blood, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 15 news outlets
blogs: 2 blogs
twitter: 51 X users

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 78 Mendeley

So far, Altmetric has seen 2 posts from 2 blogs.

From Resistance to Remission: Overcoming MEN1 Mutations by Switching Menin Inhibitors in Acute Myeloid Leukemia

Springer Nature Research Communities, 13 Apr 2026

Menin Inhibition with Revumenib for NPM1-Mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study

Stemcell science news, 15 May 2025

Scientists presented results from patients with relapsed or refractory nucleophosmin 1-mutated AML enrolled in the Phase II…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.